Post by partimefriend on Jun 9, 2016 9:07:13 GMT -5
Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of
Hepatitis B Candidate ARC-521
Bruce Given, M.D., Arrowhead chief operating officer and head of R&D said, "Arrowhead is a clear leader in the search for
curative therapies for chronic hepatitis B, which affects up to 350-400 million people worldwide. Designed to complement
ARC-520, ARC-521 targets HBV mRNA transcripts from both cccDNA and integrated DNA and is expected to be most
suitable for those patients who tend to have lower levels of viral cccDNA. We have moved very fast with this program, and
we think ARC-521 increases our leadership position in the HBV space and the race to a functional cure. Our experience
working with HBV investigators, key opinion leaders, and patients around the world has helped guide the design of an
innovative first-in-man study for ARC-521 that is intended to get to multiple dose data in patients rapidly."
files.shareholder.com/downloads/AMDA-2OTJP1/1843939681x0x895818/f7fa19af-f55a-4cb1-b568-cc3644c91a54/ARWR_News_2016_6_9_General_Releases.pdf